Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ATUL K SINGHAL

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1346256773
CMS profile
106784
Location
MESQUITE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,661.11

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,721.82 144
Travel and Lodging $933.71 2
Education $5.58 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
UCB SA $1,158.77 7
ABBVIE INC. $575.93 34
Novartis Pharmaceuticals Corporation $499.56 29
Amgen Inc. $256.09 17
UCB, Inc. $223.22 12
GlaxoSmithKline, LLC. $193.49 10
Janssen Scientific Affairs, LLC $142.35 1
AstraZeneca Pharmaceuticals LP $121.78 6
Celgene Corporation $104.09 3
Janssen Biotech, Inc. $87.71 7
Radius Health, Inc. $80.07 4
PFIZER INC. $65.88 4
Organon Llc $64.62 8
Fresenius Kabi USA, LLC $49.73 3
Octapharma USA, Inc. $23.18 1
Lilly USA, LLC $14.64 1

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ATUL K SINGHAL

NPI 1346256773 · CMS profile ID 106784

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

MESQUITE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346256773?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ATUL K SINGHAL, NPI 1346256773, CMS profile ID 106784. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346256773?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ATUL K SINGHAL, NPI 1346256773, CMS profile ID 106784. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346256773?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ATUL K SINGHAL, NPI 1346256773, CMS profile ID 106784, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1346256773?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $3,661.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–147 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $32.4105/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158603 CMS
ABBVIE INC. $28.7205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113325 CMS
Amgen Inc. $22.1805/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111710136 CMS
Organon Llc $7.6805/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136234666 CMS
Organon Llc $0.6105/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136234670 CMS
GlaxoSmithKline, LLC. $17.2305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116463956 CMS
Octapharma USA, Inc. $23.1805/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142319381 CMS
UCB, Inc. $19.1405/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143032369 CMS
ABBVIE INC. $21.1604/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113321 CMS
ABBVIE INC. $3.3304/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113323 CMS
Novartis Pharmaceuticals Corporation $11.0704/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158601 CMS
Novartis Pharmaceuticals Corporation $32.4904/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158589 CMS
ABBVIE INC. $25.0004/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113319 CMS
UCB, Inc. $9.3904/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143032365 CMS
UCB, Inc. $14.2904/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143032367 CMS
Amgen Inc. $17.9804/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111710132 CMS
Novartis Pharmaceuticals Corporation $1.7404/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158587 CMS
Radius Health, Inc. $20.7204/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089937151 CMS
UCB, Inc. $14.5103/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143032363 CMS
ABBVIE INC. $22.7203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113317 CMS
Novartis Pharmaceuticals Corporation $33.3603/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158585 CMS
Fresenius Kabi USA, LLC $14.7403/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146943826 CMS
Organon Llc $12.4603/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136234662 CMS
Amgen Inc. $21.3203/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111710130 CMS
Novartis Pharmaceuticals Corporation $7.4503/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158583 CMS
ABBVIE INC. $23.2903/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113315 CMS
UCB, Inc. $21.4203/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143032361 CMS
GlaxoSmithKline, LLC. $19.8103/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116278230 CMS
Amgen Inc. $23.2502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111710126 CMS
ABBVIE INC. $27.5002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113313 CMS
AstraZeneca Pharmaceuticals LP $19.2602/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110547794 CMS
Novartis Pharmaceuticals Corporation $0.6002/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158581 CMS
PFIZER INC. $15.0002/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131051214 CMS
Novartis Pharmaceuticals Corporation $2.8802/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158579 CMS
Novartis Pharmaceuticals Corporation $32.1102/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158577 CMS
UCB, Inc. $18.7402/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143032359 CMS
ABBVIE INC. $22.5702/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113311 CMS
GlaxoSmithKline, LLC. $15.8502/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116481263 CMS
ABBVIE INC. $5.3001/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113309 CMS
Novartis Pharmaceuticals Corporation $5.9601/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158575 CMS
UCB, Inc. $30.0001/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143032357 CMS
Amgen Inc. $24.6101/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111710128 CMS
Amgen Inc. $5.5801/29/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111710134 CMS
GlaxoSmithKline, LLC. $17.9601/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116691759 CMS
ABBVIE INC. $22.0001/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113307 CMS
ABBVIE INC. $21.8401/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113305 CMS
ABBVIE INC. $4.7401/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106113303 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,420.17 136
PY2020 $6,226.93 130
PY2021 $2,739.76 158
PY2022 $2,967.42 157
PY2023 $2,361.70 135
PY2024 $3,661.11 147
PY2025 $3,907.62 137

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,304,733.73 52
PY2024 Recipient $4,589.45 2
PY2024 Principal investigator $2,533,121.51 118
PY2023 Recipient $2,236.60 2
PY2023 Principal investigator $2,750,612.28 234
PY2022 Principal investigator $1,376,175.57 174
PY2021 Recipient $4,078.30 2
PY2021 Principal investigator $1,429,644.67 211
PY2020 Recipient $1,192.70 1
PY2020 Principal investigator $1,958,559.45 194
PY2019 Recipient $8,235.43 4
PY2019 Principal investigator $2,535,193.05 219

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,036.74 12/17/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
INSPIRE LTE study No dispute reported 06/30/2026 1246434636
Principal investigator 1 ABBVIE INC. $2,631.36 12/04/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202527084
Principal investigator 1 ABBVIE INC. $11,524.00 12/04/2025 Non-covered Recipient Entity
DHRUV SINGHAL DBA SOUTHWEST
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202527086
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $36,771.41 11/19/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
INSPIRE LTE study No dispute reported 06/30/2026 1246434639
Principal investigator 1 Novartis Pharmaceuticals Corporation $291.52 11/15/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190307661
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,166.90 11/10/2025 Non-covered Recipient Entity
Southwest Rheumatology Research Llc
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus No dispute reported 06/30/2026 1235993563
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,110.27 11/07/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434664
Principal investigator 1 ABBVIE INC. $1,354.08 11/04/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202520719
Principal investigator 1 ABBVIE INC. $1,315.68 10/09/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202516137
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,516.21 09/24/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM) No dispute reported 06/30/2026 1190307463
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,044.29 09/10/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434657
Principal investigator 1 ABBVIE INC. $4,500.00 09/03/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202508216
Principal investigator 1 Genentech, Inc. $1,386.00 08/27/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211658157
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $146.28 07/16/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434717
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,372.86 07/11/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434653
Principal investigator 1 ABBVIE INC. $3,000.00 07/04/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 1202496875
Principal investigator 1 ABBVIE INC. $2,946.24 07/02/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202496609
Principal investigator 1 UCB SA $14,038.36 06/27/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658624
Principal investigator 1 ABBVIE INC. $2,000.00 06/26/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 1202493031
Principal investigator 1 ABBVIE INC. $22,519.04 06/19/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 1202492407
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $421.46 06/16/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
INSPIRE LTE study No dispute reported 06/30/2026 1246434713
Principal investigator 1 ABBVIE INC. $6,800.00 06/12/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State No dispute reported 06/30/2026 1202491073
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $30,615.55 06/11/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434651
Principal investigator 1 ABBVIE INC. $4,223.52 06/03/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202487641
Principal investigator 1 ABBVIE INC. $750.00 05/28/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 1202486419
Principal investigator 1 Eli Lilly and Company $9,766.00 05/23/2025 Non-covered Recipient Entity
"SOUTHWEST RHEUMATOLOGY, P.A."
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875721
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $938.90 05/19/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434709
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $412.50 05/15/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434705
Principal investigator 1 ABBVIE INC. $1,392.48 05/06/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202481681
Principal investigator 1 Eli Lilly and Company $110,476.00 04/08/2025 Non-covered Recipient Entity
"SOUTHWEST RHEUMATOLOGY, P.A."
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873519
Principal investigator 1 ABBVIE INC. $1,315.68 04/03/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202470643
Principal investigator 1 Genentech, Inc. $1,004.00 04/01/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211658152
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $627.04 03/24/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434701
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $62.87 03/19/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
INSPIRE LTE study No dispute reported 06/30/2026 1246434696
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,389.57 03/17/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434660
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $29,476.22 03/14/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434642
Principal investigator 1 ABBVIE INC. $3,947.04 03/06/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202456812
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $190.00 03/05/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
INSPIRE LTE study No dispute reported 06/30/2026 1246434672
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $481.62 02/24/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
INSPIRE LTE study No dispute reported 06/30/2026 1246434692
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $331.44 02/22/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434688
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $190.00 02/10/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
INSPIRE LTE study No dispute reported 06/30/2026 1246434668
Principal investigator 1 ABBVIE INC. $2,946.24 02/05/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202444035
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,976.19 02/05/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434647
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $487.60 02/04/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434685
Principal investigator 1 Eli Lilly and Company $1,654.68 01/27/2025 Non-covered Recipient Entity
"SOUTHWEST RHEUMATOLOGY, P.A."
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873967
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $181.38 01/25/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434680
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,263.19 01/21/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235993565
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $299.59 01/21/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235993567
Principal investigator 1 UCB SA $61.07 01/17/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657111
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,546.56 01/09/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190307663
Principal investigator 1 AstraZeneca UK Limited $926,795.30 01/03/2025 Non-covered Recipient Entity
SOUTHWEST RHEUMATOLOGY RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185542146
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $38.80 01/03/2025 Non-covered Recipient Entity
Southwest Rheumatology Research
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246434676